This company has been marked as potentially delisted and may not be actively trading. Zafgen (ZFGN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ZFGN vs. MBX, RVNC, CKPT, AVTE, TSVT, SLRN, CYBN, BIOA, NLTX, and PROCShould you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include MBX Biosciences (MBX), Revance Therapeutics (RVNC), Checkpoint Therapeutics (CKPT), Aerovate Therapeutics (AVTE), 2seventy bio (TSVT), Acelyrin (SLRN), Cybin (CYBN), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Procaps Group (PROC). Zafgen vs. Its Competitors MBX Biosciences Revance Therapeutics Checkpoint Therapeutics Aerovate Therapeutics 2seventy bio Acelyrin Cybin BioAge Labs Neoleukin Therapeutics Procaps Group Zafgen (NASDAQ:ZFGN) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Do analysts recommend ZFGN or MBX? MBX Biosciences has a consensus price target of $37.50, indicating a potential upside of 192.85%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Zafgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zafgen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ZFGN or MBX more profitable? MBX Biosciences' return on equity of 0.00% beat Zafgen's return on equity.Company Net Margins Return on Equity Return on Assets ZafgenN/A -51.34% -34.55% MBX Biosciences N/A N/A N/A Do institutionals and insiders believe in ZFGN or MBX? 70.4% of Zafgen shares are held by institutional investors. 14.2% of Zafgen shares are held by insiders. Comparatively, 52.2% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor ZFGN or MBX? In the previous week, MBX Biosciences had 1 more articles in the media than Zafgen. MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Zafgen. MBX Biosciences' average media sentiment score of 1.91 beat Zafgen's score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Zafgen Neutral MBX Biosciences Very Positive Which has stronger valuation & earnings, ZFGN or MBX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZafgenN/AN/A-$45.41M-$1.07-2.99MBX BiosciencesN/AN/AN/AN/AN/A SummaryMBX Biosciences beats Zafgen on 8 of the 9 factors compared between the two stocks. Get Zafgen News Delivered to You Automatically Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZFGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZFGN vs. The Competition Export to ExcelMetricZafgenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.90M$780.11M$5.45B$8.92BDividend YieldN/A4.84%5.22%4.00%P/E Ratio-3.331.3027.2720.07Price / SalesN/A230.48428.46118.22Price / CashN/A23.4426.2128.59Price / Book2.376.237.925.58Net Income-$45.41M-$27.94M$3.17B$248.65M Zafgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZFGNZafgenN/A$3.20+2.9%N/A-57.8%$119.90MN/A-3.3338MBXMBX Biosciences3.0783 of 5 stars$11.71+2.6%$37.50+220.4%N/A$387.72MN/A0.0036RVNCRevance Therapeutics2.7508 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500CKPTCheckpoint Therapeutics0.423 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210AVTEAerovate TherapeuticsN/A$9.99+8.7%N/A-80.2%$289.56MN/A-3.3420High Trading VolumeTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135CYBNCybin3.1362 of 5 stars$9.03+7.7%$86.00+852.0%N/A$207.79MN/A-2.0650Analyst RevisionHigh Trading VolumeBIOABioAge LabsN/A$4.23+2.4%N/AN/A$151.65MN/A0.00N/ANLTXNeoleukin TherapeuticsN/A$14.95-7.5%N/A-41.1%$140.50MN/A-4.8190High Trading VolumePROCProcaps GroupN/A$0.95-40.3%N/A-62.0%$107.18M$409.92M0.004,900Gap DownHigh Trading Volume Related Companies and Tools Related Companies MBX Alternatives RVNC Alternatives CKPT Alternatives AVTE Alternatives TSVT Alternatives SLRN Alternatives CYBN Alternatives BIOA Alternatives NLTX Alternatives PROC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZFGN) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
